Background: Severe alcoholism can be associated with significant nutritional and vitamin deficiency, especially vitamin B1 (thiamine) which is associated with neurological deficits impacting mood and cognition. Alcohol consumption was reduced among female but not male alcoholics after supplementation with the high potency thiamine analog benfotiamine (BF). We examined the relationship between lifetime alcoholism severity, psychiatric symptoms and response to BF among the alcohol dependent men from this cohort.
Methods: Eighty-five adult men (mean age=48±8 years) meeting DSM-IV-TR criteria for a current alcohol use disorder who were abstinent <30days participated in a randomized, double-blind, placebo-controlled trial of 600mg BF vs placebo (PL) for 6 months. Psychometric testing included a derived Lifetime Alcoholism Severity Score (AS), Symptom Checklist 90R (SCL-90R), and the Barratt Impulsivity Scale (BIS) at baseline and at 6 months.
Results: Baseline SCL-90-R scale scores for men with high alcoholism severity (AS≥24; N=46 HAS) were significantly greater than for men with low alcoholism severity (AS<24; N=39 LAS), but BIS scores did not differ. MANOVA modeling at follow-up (N=50 completed subjects) identified a significant treatment effect (F=2.5, df=10, p<0.03) and treatment×alcoholism severity level interaction (F=2.5, dfnum=10, dfden=30, p<0.03) indicating reduced SCL-90-R scores among BF treated, HAS males. Above normal plasma thiamine levels at follow-up predicted reduced depression scores in a BF-treated subset (F=3.2, p<0.09, N=26).
Conclusion: BF appears to reduce psychiatric distress and may facilitate recovery in severely affected males with a lifetime alcohol use disorder and should be considered for adjuvant therapy in alcohol rehabilitation.
Trial Registration: #NCT00680121 High Dose Vitamin B1 to Reduce Abusive Alcohol Use.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550087 | PMC |
| http://dx.doi.org/10.1016/j.drugalcdep.2015.03.032 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Polarity-Sensitive fluorescent probes based on triphenylamine for fluorescence lifetime imaging of lipid droplets.
Spectrochim Acta A Mol Biomol Spectrosc
January 2025
School of Basic Medical Sciences, Guizhou Medical University, Guiyang 550025, PR China. Electronic address:
Non-alcoholic fatty liver disease (NAFLD) is a disease closely associated with metabolic abnormalities. Lipid droplets (LDs) serve as organelles that store intracellular neutral lipids and maintain cellular energy homeostasis. Their abnormalities can cause metabolic disorders and disease, which is also one of the distinctive characteristics of NAFLD patients.
View Article and Find Full Text PDFLifetime and active use of electronic cigarettes among Brazilian adolescents: The 2019 national school health survey - PeNSE 2019.
Public Health
December 2024
Post-graduate Program in Health in the Vital Cycle, Faculty of Medicine, Health Science Centre, Catholic University of Pelotas, Brazil. Electronic address:
Article Synopsis
- The study analyzed the prevalence and factors linked to e-cigarette use among Brazilian adolescents based on data from the National School Health Survey (PeNSE 2019).
- It found that 20.7% of males and 15.4% of females had experimented with e-cigarettes, while 4.1% of males and 2.6% of females had used them in the last 30 days.
- Significant associations were noted between e-cigarette use and factors like hookah use and alcohol consumption, indicating that those with a history of these behaviors were more likely to experiment with or recently use e-cigarettes.
Demographic and clinical characteristics associated with utilization of alcohol use disorder treatment in a multicenter study of patients with alcohol-associated cirrhosis.
Alcohol Clin Exp Res (Hoboken)
December 2024
Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, California, USA.
Article Synopsis
- Treatment for alcohol use disorder (AUD) is important for improving health outcomes in patients with alcohol-associated cirrhosis, yet it remains underutilized, especially among socioeconomically disadvantaged groups.
- A study of 196 diverse patients revealed that 67% had ever utilized AUD treatment, while only 32% accessed treatment in the last year; younger patients and those with worse mental health symptoms were more likely to seek treatment.
- Factors such as older age and better liver disease quality of life were associated with lower treatment utilization, while those with significant anxiety or depression tended to seek treatment more frequently.
Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease.
J Hepatol
November 2024
CHRU de Lille, Hôpital Claude Huriez, Rue M. Polonovski CS 70001, 59 037 Lille Cedex, France. Electronic address:
In this position statement, we explore the intricate relationship between alcohol intake and metabolic dysfunction in the context of the 2023 nomenclature update for steatotic liver disease (SLD). Recent and lifetime alcohol use should be accurately assessed in all patients with SLD to facilitate classification of alcohol use in grams of alcohol per week. Alcohol biomarkers (i.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!